{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:55:17Z","timestamp":1740142517522,"version":"3.37.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA237619"],"award-info":[{"award-number":["CA237619"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:48:07Z","timestamp":1708645687000},"page":"241-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Voices in Rheumatic Immune-related Adverse Events"],"prefix":"10.1016","volume":"50","author":[{"given":"Kara N.","family":"Corps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rdc.2024.01.006_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/fon-2022-0767","article-title":"Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients","volume":"19","author":"Grivas","year":"2023","journal-title":"Future Oncol"},{"issue":"32","key":"10.1016\/j.rdc.2024.01.006_bib2","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.2217\/fon-2021-0697","article-title":"Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study","volume":"17","author":"Lo","year":"2021","journal-title":"Future Oncol"},{"issue":"46","key":"10.1016\/j.rdc.2024.01.006_bib3","doi-asserted-by":"crossref","first-page":"e5375","DOI":"10.1097\/MD.0000000000005375","article-title":"Preferences of German melanoma patients for interferon (IFN) alpha-2b toxicities (the DeCOG \u201cGERMELATOX survey\u201d) versus melanoma recurrence to quantify patients\u2019 relative values for adjuvant therapy","volume":"95","author":"Kaehler","year":"2016","journal-title":"Medicine"},{"issue":"40","key":"10.1016\/j.rdc.2024.01.006_bib4","doi-asserted-by":"crossref","first-page":"26217","DOI":"10.18632\/oncotarget.25439","article-title":"The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians","volume":"9","author":"Kahler","year":"2018","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.rdc.2024.01.006_bib5","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1002\/cam4.3191","article-title":"Therapy preferences in melanoma treatment-willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease","volume":"9","author":"Weiss","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.rdc.2024.01.006_bib6","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/cam4.2940","article-title":"Cancer patients' experiences with immune checkpoint modulators: a qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.rdc.2024.01.006_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00520-023-07965-3","article-title":"A\u00a0qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer","volume":"31","author":"Hou","year":"2023","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.006_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.21670","article-title":"Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma","volume":"187","author":"Kamminga","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.01.006_bib9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","article-title":"Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy","volume":"27","author":"Levy","year":"2019","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.006_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s12885-020-07215-3","article-title":"Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study","volume":"20","author":"Jamieson","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.006_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s41687-022-00533-z","article-title":"Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow","volume":"6","author":"Kastrati","year":"2022","journal-title":"J Patient-Rep Outcom"},{"issue":"15","key":"10.1016\/j.rdc.2024.01.006_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15154004","article-title":"Learning needs of patients with cancer and a pre-existing autoimmune disease who are candidates to receive immune checkpoint inhibitors","volume":"15","author":"Lopez-Olivo","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.006_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1098-240X(199704)20:2<169::AID-NUR9>3.0.CO;2-I","article-title":"Interpretive description: a noncategorical qualitative alternative for developing nursing knowledge","volume":"20","author":"Thorne","year":"1997","journal-title":"Res Nurs Health"},{"issue":"3","key":"10.1016\/j.rdc.2024.01.006_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/DCC.0000000000000240","article-title":"Exploring the philosophical, paradigmatic, conceptual-theoretical underpinnings of qualitative research: a focus on a phenomenological study in intensive care unit","volume":"36","author":"Cypress","year":"2017","journal-title":"Dimens Crit Care Nurs"},{"issue":"4","key":"10.1016\/j.rdc.2024.01.006_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40271-020-00428-5","article-title":"Patient experiences with avelumab in treatment-naive metastatic merkel cell carcinoma: longitudinal qualitative interview findings from javelin merkel 200, a registrational clinical trial","volume":"13","author":"Lambert","year":"2020","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.rdc.2024.01.006_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-018-4316-9","article-title":"Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada","volume":"27","author":"Cheung","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rdc.2024.01.006_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2021.08.026","article-title":"Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: a Delphi study","volume":"157","author":"Da Silva Lopes","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.rdc.2024.01.006_bib18","doi-asserted-by":"crossref","first-page":"e34073","DOI":"10.2196\/34073","article-title":"The experiences of patients with adjuvant and metastatic melanoma using disease-specific social media communities in the advent of novel therapies (excite project): social media listening study","volume":"8","author":"Faust","year":"2022","journal-title":"JMIR Cancer"},{"key":"10.1016\/j.rdc.2024.01.006_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2024.01.006_bib20","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s00432-020-03336-1","article-title":"Patient expectations are better for immunotherapy than traditional chemotherapy for cancer","volume":"146","author":"Ihrig","year":"2020","journal-title":"J\u00a0Cancer Res Clin"},{"key":"10.1016\/j.rdc.2024.01.006_bib21","first-page":"142","article-title":"The experience of patients receiving pembrolizumab therapy for metastatic melanoma","volume":"13","author":"Dhillon","year":"2017","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:20:09Z","timestamp":1729020009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000061"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Voices in Rheumatic Immune-related Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}